At a Glance

Launched in: 2006
Currently working with: 27 countries

USAID Investment
2.8 billion treatments delivered
1.4 billion people treated
$26 billion leveraged in donated drugs
7 million individuals trained strengthening the expertise and capacity of country partners

Health Impact
10 USAID-supported countries have eliminated at least one NTD as a public health problem
People no longer requiring treatment for lymphatic filariasis: 315 million
People no longer requiring treatment for trachoma: 151 million
People no longer requiring treatment for onchocerciasis: 10 million

The Future
15 countries will eliminate at least one NTD as a public health problem within 5 years
12 USAID-supported countries are developing NTD sustainability plans

Neglected Tropical Diseases

Neglected tropical diseases (NTDs) cause illness and lifelong disabilities for more than a billion of the poorest and most marginalized people worldwide. Not addressing NTDs traps individuals and communities in poverty, undermines growth and development, and impairs progress towards achieving global health and development goals. For 15 years, the Agency has supported more than 30 countries to combat five of the most common NTDs.

USAID targets five of the most common NTDs that have proven, cost-effective health interventions:

- Lymphatic Filariasis (elephantiasis)
- Blinding Trachoma
- Onchocerciasis (river blindness)
- Schistosomiasis (snail fever)
- Soil Transmitted Helminths (hookworm, roundworm, whipworm)

Our Objectives

The United States Agency for International Development (USAID) works alongside endemic countries and with global, regional, and in-country partners to improve health and end NTDs. USAID’s NTD Program has four key objectives.

Key objectives and approaches to accelerate progress on ending NTDs:

- **Controlling & eliminating diseases**
  - Mapping to find communities at-risk of these NTDs
  - Treating at-risk communities with safe, effective, donated medicines — treating for more than one disease at a time where appropriate
  - Measuring progress and documenting impact of the control and elimination of NTDs

- **Strengthening the scientific & program evidence base**
  - Investing in operational research to generate and advance evidence that can then be used to remove barriers to progress, improve program efficiencies, and protect public health gains
  - Supporting diagnostic innovations to improve delivery of NTD services, use of program resources, and measuring progress towards control and elimination targets

- **Supporting sustainable country-led programs**
  - Supporting government-developed, multi-sectoral sustainability plans for NTD prevention and treatment
  - Reinforcing national governance of NTD programs
  - Strengthening health systems to deliver NTD services

**Strengthening & expanding partnerships**

- Partnering with host governments, pharmaceutical companies, private and government donors, non-governmental organizations, and researchers

*Cumulative results from 2006 to 2019
**Results Over the Years**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$404 million</td>
<td>$507 million</td>
<td>$577 million</td>
<td>$686 million</td>
<td>$949 million</td>
<td>$1 billion</td>
<td>$2.5 billion</td>
<td>$2.1 billion</td>
<td>$2.2 billion</td>
<td>$4.6 billion</td>
<td>$3.3 billion</td>
<td>$3.2 billion</td>
<td>$3.7 billion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>36 million</td>
<td>58 million</td>
<td>130 million</td>
<td>160 million</td>
<td>208 million</td>
<td>244 million</td>
<td>233 million</td>
<td>239 million</td>
<td>299 million</td>
<td>390 million</td>
<td>318 million</td>
<td>268 million</td>
<td>194 million</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Private Sector Donations**

Our success is underpinned by a dynamic public-private partnership with the pharmaceutical industry, which enables USAID to carry out the largest integrated NTD program in the world, ensuring that treatments reach those in need. Leading pharmaceutical companies have made unprecedented pledges to tackle the most common NTDs by providing drugs free of charge.

- Eisai Co., Ltd.
- Johnson & Johnson
- Merck KGaA
- Pfizer
- GlaxoSmithKline
- Merck & Co. Inc.

**To date:**
Every $1 invested by the U.S. Government leverages $26 in donated medicines for mass treatment campaigns totalling $26 BILLION in value

**Country Successes**

USAID-supported countries that have eliminated at least one disease, verified by the WHO:


USAID-supported country governments that have completed an NTD sustainability plan:

- Ivory Coast (2020), Senegal (2021), Uganda (2021)

**Where We Work**

USAID-supported countries that have eliminated at least one NTD, verified by the WHO:


USAID-supported country governments that have completed an NTD sustainability plan:

- Ivory Coast (2020), Senegal (2021), Uganda (2021)

**KEY**

- OEPA Program
- USAID Direct-Supported
- Bold: Eliminated at least one NTD
- Bold: Developed a sustainability plan

- LATIN AMERICA & THE CARIBBEAN
  - Brazil
  - Colombia
  - Ecuador
  - Guatemala
  - Mexico
  - Venezuela

- AFRICA
  - Benin
  - Burkina Faso
  - Cameroon
  - Democratic Republic of the Congo
  - Ethiopia
  - Ghana
  - Guinea
  - Ivory Coast
  - Mali
  - Mozambique
  - Niger
  - Nigeria
  - Senegal
  - Sierra Leone
  - Tanzania
  - Togo
  - Uganda

- ASIA
  - Bangladesh
  - Cambodia
  - Indonesia
  - Laos
  - Nepal
  - Philippines
  - Vietnam

**U.S.AGENCY FOR INTERNATIONAL DEVELOPMENT**

The United States Agency for International Development is an international development agency and a catalytic actor driving development results.